glp -1 drugs New GLP-1 Guidelines for Type 2 Diabetes in 2025 America's Poison Centers - GLP-1
Description
ADMA, Asymmetric dimethylarginine (an endogenous inhibitor of nitric oxide synthase, marker of endothelial dysfunction)
As per Bloomberg , Aspen is targeting regulatory approval in Canada between May and September for its generic GLP1 obesity treatment and expects Canada will likely be the first market for its GLP1 product
ROR = 1.1, 95% CI 1.091.11) Gastrointestinal disorders (n = 33,685
doi: 10.1172/JCI115997 51 PetersenKFSullivanJT
PMID 12217892
PMC, 2013
